GHRP-6 — Literature-Reported Ranges & Study Protocols

Read this first

Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.

Compound at a glance

Class: Hexapeptide growth-hormone secretagogue
Reported half-life: Roughly 20–30 minutes
Routes used in the literature: Subcutaneous and intravenous in published pharmacology
Also written as: —

What the published studies reported

Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.

Human GH-release pharmacology

Reported quantity: 1 µg/kg intravenously as the classic provocative figure
Frequency: Single administration per test
Study duration: Sampling over 120 minutes

1 µg/kg IV is the standard reference figure across the older endocrine literature.

Subcutaneous comparative studies

Reported quantity: 100 µg per administration in adult comparative work
Frequency: One to three times daily in multi-day arms
Study duration: Days to a few weeks

Cortisol and prolactin rise alongside GH, unlike with ipamorelin.

Dosage chart

These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.

GHRP-6 · 10 mg Vial

GHRP-6 is dosed at 100 mcg–300 mcg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → ~ 3.33 mg/mL concentration.
Typical daily range: 300–900 mcg total (split into 3 doses with gradual titration).
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 7 days.

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Week/Phase	Dose per Injection (mcg)	Units (per injection) (mL)
Weeks 1–2	100 mcg	3 units (0.03 mL)
Weeks 3–4	200 mcg	6 units (0.06 mL)
Weeks 5–12	300 mcg	9 units (0.09 mL)

Source chart on peptidedosages.com

Mixed with 3 ml of bacteriostatic water

The same arithmetic for every vial size GHRP-6 is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.

GHRP-6 · 3 ml bacteriostatic water

Vial size	Concentration	Per 1 unit	300 mcg =	900 mcg =
5 mg	1.67 mg/ml	17 mcg	18 units	54 units
10 mg	3.33 mg/ml	33 mcg	9.0 units	27 units

Unit columns use the range reported for this compound (300 mcg–900 mcg). Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.

Reconstitution maths

A 5 mg vial in 2.5 mL of bacteriostatic water gives 2 mg/mL; 0.05 mL draws 100 µg.

Open the reconstitution calculator

How to read these figures

Non-selective secretagogue: published data shows cortisol and prolactin movement.
Receptor desensitisation with repeated exposure is documented in the pharmacology literature.
Appetite stimulation is a consistently reported feature, not an incidental one.

Sources and citations

These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.

[1]
Oral administration of growth hormone (GH)-releasing peptide stimulates GH secretion in normal men
Bowers CY, Sartor AO, Reynolds GA, Badger TM. · Journal of Clinical Endocrinology & Metabolism · 1992 · PMID 1592884
Ten normal men received oral GHRP doses of 30, 100, and 300 micrograms/kg to compare GH-releasing effects with intravenous administration.
View the record
[2]
Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers
Cabrales A, Gil J, Fernandez E, et al. · European Journal of Pharmaceutical Sciences · 2012 · PMID 23099431
Nine healthy male volunteers received a single intravenous dose of GHRP-6 to characterize its pharmacokinetic profile.
View the record
[3]
Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature
Bellone J, Ghizzoni L, Aimaretti G, et al. · European Journal of Endocrinology · 1995 · PMID 7581965
Children with short stature received oral GHRP-6 to assess GH-releasing effects, establishing an oral dosing regimen in a pediatric population.
View the record

Search the databases yourself

Read the GHRP-6 research brief

Other growth hormone compounds

AOD-9604hGH fragment 176-191 CJC-1295 (no DAC)Tetra-substituted GHRH (1-29) analogue CJC-1295 (no DAC) + IpamorelinGHRH analogue + selective ghrelin-receptor agonist blend CJC-1295 with DACGHRH analogue with albumin-binding drug affinity complex

All research protocols

Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.